Ki-67 labeling index and HIF-1α expression delineate prognostic heterogeneity within FNCLCC grade 2 soft-tissue sarcoma: a multicenter cohort study

Soft-tissue sarcomas are rare cancers that begin in the muscles, fat, nerves, or other connective tissues of the body. While doctors have long used a standard system to grade these tumors based on how they look under a microscope, this system has a blind spot. It groups a wide variety of tumors into a single category called "grade 2." This middle category is a mixed bag; it contains some tumors that behave relatively calmly and others that are dangerously aggressive, yet they all receive the same label. This lack of distinction makes it difficult for doctors to predict exactly how a specific patient will fare or to decide the best course of treatment. To solve this, researchers have begun looking for biological clues hidden inside the tumor cells themselves. Two such clues are a measure of how fast the cells are dividing and a signal that shows how the tumor is surviving in low-oxygen environments. By combining these two signals, scientists hope to separate the calm tumors from the dangerous ones within that confusing middle group.

A team of researchers from five medical centers across China set out to test this idea using a large group of patients. They gathered data from 320 adults who had undergone surgery to remove their primary soft-tissue sarcoma between 2014 and 2020. The team split these patients into two groups: a larger group to help them develop their method, and a smaller, independent group to test if the method worked on new people. The researchers focused specifically on the patients whose tumors had been classified as grade 2 by the standard system. For every single tumor in this group, they performed a detailed analysis of two specific proteins. The first protein, known as Ki-67, acts as a counter for cell division; a high number of these proteins means the tumor cells are multiplying rapidly. The second protein, called HIF-1α, is a marker of hypoxia, or low oxygen. Tumors often grow so fast that they outstrip their blood supply, forcing them to adapt to a lack of oxygen. This protein helps the tumor survive that stress.

The researchers used a sophisticated computer system to count these proteins with high precision. They looked at thousands of cells in each tumor sample to calculate the exact percentage of cells showing high levels of these markers. Based on these counts, they sorted the grade 2 tumors into three new categories. The first group, the "double-low" group, had tumors with low levels of both cell division and oxygen-stress signals. The second group, the "single-high" group, had tumors that were high in only one of the two markers. The third group, the "double-high" group, had tumors that were high in both. The researchers then tracked the patients for several years to see who survived and who did not, comparing the outcomes of these three new groups against each other and against the standard grade 3 tumors, which are known to be the most dangerous.

The results revealed a clear and striking pattern. The patients in the "double-low" group had the best outcomes, with survival rates similar to those with the least aggressive tumors. However, the patients in the "double-high" group faced a significantly different reality. Their survival rates were much lower, dropping to levels that were close to those of the most dangerous grade 3 tumors. In the initial group of patients, those with double-high tumors were far more likely to die from the disease compared to those with double-low tumors. When the researchers tested this same classification on the second, independent group of patients, the pattern held true. The double-high group again showed much worse survival than the double-low group, confirming that this biological signature is a reliable indicator of danger.

The study also examined the middle group, the "single-high" tumors. In the first group of patients, these tumors appeared to be more dangerous than the double-low ones. However, when tested in the second group, this difference was not statistically clear. This suggests that while having one high marker might be a warning sign, it is the combination of both high markers that truly defines the most aggressive subset of grade 2 tumors. The researchers found that the double-high tumors occupied a risk position close to that of grade 3 tumors, even though they still looked like grade 2 under a microscope. However, the statistical estimates were imprecise, and the study did not establish that the risk was truly equivalent to grade 3. This finding suggests that the standard grading system misses a critical layer of information that can be uncovered by looking at these two specific biological signals.

Despite these strong findings, the researchers were careful not to declare the system perfect. While the new classification helped doctors rank patients by risk more accurately, it did not significantly improve the ability to predict the exact number of years a patient would live or to calculate the precise probability of survival for every individual. The study showed that adding these biological markers improved the overall picture, but it did not replace the need for the existing grading system. The "single-high" category, in particular, remains uncertain and requires more study to understand if it represents a single type of dangerous tumor or two different types that happen to look similar.

Ultimately, this work offers a refined way to look at soft-tissue sarcomas. It confirms that within the broad category of grade 2 tumors, there is a distinct subgroup that behaves with the ferocity of the most aggressive cancers. By identifying these "double-high" tumors through the combined presence of rapid cell division and oxygen-stress adaptation, doctors may eventually be able to offer more tailored treatments to the patients who need them most. The study does not change the current rules for grading tumors, but it provides a powerful new lens through which to view them, suggesting that the future of cancer care may lie in combining what the microscope sees with what the biology reveals.